Parallax Volatility Advisers
ENTA icon

Parallax Volatility Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Parallax Volatility Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,000
Closed -$704K – 3106
2021
Q2 		$704K Hold
16,000
– – ﹤0.01% 2067
2021
Q1 		$789K Buy
+16,000
New +$798K ﹤0.01% 2189
2019
Q2 		– Sell
-12,500
Closed -$1.19M – 2815
2019
Q1 		$1.19M Buy
+12,500
New +$1.12M ﹤0.01% 1198

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallax Volatility Advisers's ENTA Position: Q1 2022 in Review

Parallax Volatility Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q1 2022, closing a stake of 5,049 shares — an estimated $378K sold.

Parallax Volatility Advisers first reported a position in ENTA in Q4 2017 and held it in 4 quarters. The position peaked at $378K in Q4 2021. 170 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

  • Parallax Volatility Advisers reported no remaining Enanta Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,049 Enanta Pharmaceuticals shares in Q1 2022, an estimated $378K.
  • Parallax Volatility Advisers first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Parallax Volatility Advisers's Enanta Pharmaceuticals position peaked at $378K in Q4 2021.
  • 170 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on Parallax Volatility Advisers's 13F filing for Q1 2022, filed 16 May 2022.